Mark Diamond
Voorzitter bij DIMERIX LIMITED
Vermogen: 219 288 $ op 30-04-2024
Actieve functies van Mark Diamond
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| DIMERIX LIMITED | Voorzitter | 12-01-2023 | - |
Loopbaan van Mark Diamond
Eerdere bekende functies van Mark Diamond
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| PERCHERON THERAPEUTICS LIMITED | Directeur/Bestuurslid | 31-10-2001 | 12-05-2023 |
| Algemeen Directeur | 31-10-2001 | 12-05-2023 | |
| FH Faulding & Co. Ltd. | Corporate Officer/Principal | - | - |
| Faulding Pharmaceuticals Plc | Corporate Officer/Principal | - | - |
Alpharma Specialty Pharma LLC
 Alpharma Specialty Pharma LLC Medical DistributorsDistribution Services Part of Pfizer Inc., Alpharma Specialty Pharma LLC is a company that distributes multi-source injectable pharmaceutical drugs. The company is based in Paramus, NJ. | Corporate Officer/Principal | - | - |
Opleiding van Mark Diamond
| Monash University | Undergraduate Degree |
| Macquarie University | Masters Business Admin |
Statistieken
Internationaal
| Australië | 6 |
| Verenigde Staten | 2 |
| Verenigd Koninkrijk | 2 |
Operationeel
| Corporate Officer/Principal | 3 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
| Distribution Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| PERCHERON THERAPEUTICS LIMITED | Health Technology |
| DIMERIX LIMITED | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Alpharma Specialty Pharma LLC
Alpharma Specialty Pharma LLC Medical DistributorsDistribution Services Part of Pfizer Inc., Alpharma Specialty Pharma LLC is a company that distributes multi-source injectable pharmaceutical drugs. The company is based in Paramus, NJ. | Distribution Services |
| Faulding Pharmaceuticals Plc | |
| FH Faulding & Co. Ltd. | Health Technology |
- Beurs
- Insiders
- Mark Diamond
- Ervaring
